Biotechnology
15 July 2025 After almost 30 years as head of IP at Bayer, Jörg Thomaier is to retire and is handing the baton to Dorian Immler. Speaking to Sarah Speight, the pair explain what makes a good IP strategy, why the UPC is largely “useless” without SPCs, and more.
Latest Features
Europe
For those willing to undertake the complexity, in vivo cell therapy could redefine the economics and logistics of cell-based treatment, says Adam Gregory of Mewburn Ellis.
Americas
Will this year be defined by a concerted shift towards ‘One Health’? Simon Kiddle and Rebecca Tollervey of Mewburn Ellis explore.
Americas
Key developments for the industry this year include a more pro-patent administration and USPTO changes, say Carla Ji-Eun Kim and Deborah Sterling of Sterne Kessler.
Americas
Key similarities and differences between the patent systems, particularly in biotech, offer lessons and opportunities for rightsholders, say Daniela Fasoli of Simões Propriedade Intelectual and Jeffrey Morton of Haynes and Boone.
Asia
Free trade zones in Beijing, Shanghai, Guangdong, and Hainan are designed to attract capital into China’s fast-growing healthcare sectors, says Li Mi of Lusheng.
Americas
Well-drafted contracts and ironclad tech security can save time and money when an ex-employee steals IP ‘like sugar packets in Starbucks’, finds Tom Phillips.
Biotechnology
The shift towards preventative pharmaceuticals could open new, and highly valuable, markets but it must be strengthened by patent rights, says Sam Andrews, senior paralegal at Powell Gilbert.
Biotechnology
AI has the potential to revolutionise patent examination but uneven adoption of the technology could undermine fairness in the system, says Matthew Veale of Patsnap.
More News
19 June 2025 The biotech firm strikes again over Eylea after Amgen launches biosimilar | Regeneron claims Amgen infringed agreed ‘patent dance’ | Follows other lawsuits aimed at protecting Eylea.
17 June 2025 Court affirms infringement of patent covering gene expression technology | Curio Bioscience cannot sell related products in three EU countries | Decision is “further testament to 10x Genomic’s strategic use of IP”, 10x counsel tells LSIPR.
10 June 2025 Office’s acting director lifts severe penalties against patent owner following Federal Circuit remand | Issues separate decision highlighting consequences of “lengthy awareness” of patent portfolio.
3 June 2025 New York court finds Ethicon breached agreement with ChemImage over advanced imaging technologies | Parties dispute damages for IP ‘impairment’.
3 June 2025 The new hire brings over 20 years of experience in patent prosecution and litigation involving pharmaceuticals, molecular biology and medical technologies.
29 May 2025 Ravi Srinivasan of JA Kemp explores strategies for identifying, prosecuting, and defending follow-on patent applications after a therapeutic product enters the public domain. The session at LSPN covers patents based on clinical trial data and polymorphs of small molecule drugs.
27 May 2025 New hire is a specialist in pharmaceutical regulatory matters, complex patent disputes, and cross-border transactional support for biotech.
Get up-to-date information on all our publications and events
Get critical life sciences news direct to your inbox